Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Urine sediment

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    48 result(s) found for: Urine sediment. Displaying page 2 of 3.
    « Previous 1  2  3  Next»
    EudraCT Number: 2018-000037-13 Sponsor Protocol Number: PTK0796-AP-17202 Start Date*: 2018-09-04
    Sponsor Name:Paratek Pharma, LLC, a wholly-owned subsidiary of Paratek Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blinded, Adaptive Phase 2 Study to Evaluate the Safety and Efficacy of IV or IV/PO Omadacycline and IV/PO Levofloxacin in the Treatment of Adults with Acute Pyelonephritis
    Medical condition: Acute Pyelonephritis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10001032 Acute pyelonephritis LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2013-002416-27 Sponsor Protocol Number: INFECIR2 Start Date*: 2013-10-23
    Sponsor Name:Fundacio Clinic per a la recerca biomedica
    Full Title: Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mo...
    Medical condition: Patients with advanced cirrhosis (serum creatinine > 1.2 mg/dl, serum sodium < 130 mEq/l and/or serum bilirubin > 4 mg/dl), signs of systemic inflammation and urinary infection, pneumonia, skin/sof...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10019805 - Hepatobiliary disorders 10024667 Liver cirrhosis LLT
    16.0 10019805 - Hepatobiliary disorders 10008954 Chronic liver disease and cirrhosis LLT
    16.0 10019805 - Hepatobiliary disorders 10019641 Hepatic cirrhosis PT
    16.0 10019805 - Hepatobiliary disorders 10064704 Decompensated cirrhosis LLT
    16.0 10019805 - Hepatobiliary disorders 10009213 Cirrhosis of liver LLT
    16.0 10019805 - Hepatobiliary disorders 10009211 Cirrhosis liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) ES (Ongoing) IT (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) IE (Prematurely Ended) GB (Prematurely Ended) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001619-21 Sponsor Protocol Number: OPTIMAB Start Date*: 2019-10-07
    Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE- IDIBELL
    Full Title: PILOT STUDY FOR THE OPTIMITZATION OF THE MAINTENANCE DOSE OF ECULIZUMAB ACCORDING TO THE WEIGHT IN ADULT PATIENTS WITH ATYPIC HEMOLYTIC UREMIC SYNDROME
    Medical condition: ATYPICAL HEMOLYTIC UREMIC SYNDROME
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004851 10079841 Atypical hemolytic uremic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003767-25 Sponsor Protocol Number: APL2-C3G-310 Start Date*: 2022-03-08
    Sponsor Name:Apellis Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoprolif...
    Medical condition: complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10038359 Renal and urinary disorders SOC
    20.0 10038359 - Renal and urinary disorders 10077827 C3 glomerulopathy PT
    21.1 10038359 - Renal and urinary disorders 10027168 Membranoproliferative glomerulonephritis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) CZ (Completed) BE (Completed) AT (Trial now transitioned) FR (Completed) PL (Completed) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003364-51 Sponsor Protocol Number: AUR-VCS-2012-01 Start Date*: 2014-10-24
    Sponsor Name:Aurinia Pharmaceuticals Inc.
    Full Title: A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) with Placebo in Achieving Remission in Patients with Active Lupus Nephritis
    Medical condition: Active lupus nephritis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-004868-35 Sponsor Protocol Number: AT-301 Start Date*: 2018-08-23
    Sponsor Name:Allecra Therapeutics SAS
    Full Title: A Phase 3, Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Cefepime- AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Ur...
    Medical condition: Complicated urinary tract infections including acute pyelonephritis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10037597 Pyelonephritis acute PT
    20.0 10021881 - Infections and infestations 10046577 Urinary tract infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed) ES (Completed) BG (Completed) SK (Completed) PL (Completed) HU (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2017-003772-31 Sponsor Protocol Number: IT001-302 Start Date*: 2018-12-07
    Sponsor Name:Iterum Therapeutics International Limited
    Full Title: A prospective, Phase 3, randomized, multi-center, double-blind, double dummy study of the efficacy, tolerability and safety of intravenous sulopenem followed by oral sulopenem-etzadroxil with probe...
    Medical condition: Complicated urinary tract infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) EE (Completed) CZ (Completed) BG (Completed) SK (Completed) HR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003201-34 Sponsor Protocol Number: U2970g Start Date*: 2016-08-07
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis
    Medical condition: ISN/RPS 2003 Class III or IV Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-003975-80 Sponsor Protocol Number: SHORTCUT Start Date*: 2018-03-07
    Sponsor Name:Academic Medical Center
    Full Title: Shorter treatment of catheter related urinary tract infections
    Medical condition: Catheter related urinary tract infection (CAUTI)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001451-13 Sponsor Protocol Number: VNRX-5133-201 Start Date*: 2019-07-02
    Sponsor Name:Venatorx Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Active-controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults with Complicated Urinary Tract Infecti...
    Medical condition: Complicated Urinary Tract Infections, Including Acute Pyelonephritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10046577 Urinary tract infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) CZ (Completed) HU (Completed) BG (Completed) HR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-005161-31 Sponsor Protocol Number: AT-201 Start Date*: 2017-07-04
    Sponsor Name:Allecra Therapeutics SAS
    Full Title: Randomized, Double-Blind, Multi-Center Study of Cefepime/AAI101 in Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis
    Medical condition: Complicated urinary tract infections including acute pyelonephritis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021881 - Infections and infestations 10037597 Pyelonephritis acute PT
    19.1 10021881 - Infections and infestations 10046577 Urinary tract infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-023396-25 Sponsor Protocol Number: SM101-201-sle-10 Start Date*: 2011-09-22
    Sponsor Name:SuppreMol GmbH
    Full Title: Phase IIa, 2:2:1 randomised, double-blind, placebo-controlled, parallel group, multi-centre clinical trial to investigate the safety, efficacy and pharmacokinetics of recombinant human soluble F...
    Medical condition: Systemic lupus erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) CZ (Completed) PL (Completed) NL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005544-18 Sponsor Protocol Number: PB-102-F03 Start Date*: 2015-04-29
    Sponsor Name:Protalix Ltd.
    Full Title: A Multi Center Extension Study of PRX-102 Administered by Intravenous Infusions Every 2 Weeks for 24 Months to Adult Fabry Patients
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003230-93 Sponsor Protocol Number: CCFZ533X2202 Start Date*: 2018-05-09
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, placebo-controlled, patient and investigator blinded study investigating the safety, tolerability, pharmacokinetics and preliminary efficacy of multiple doses of CFZ533 in patients wi...
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005707-32 Sponsor Protocol Number: MK-7655-003 Start Date*: 2012-07-13
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients wit...
    Medical condition: Patients with Complicated Urinary Tract Infection at least 18 years of age, with a diagnosis of either complicated cUTI or acute pyelonephritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10046544 Urinary infection LLT
    14.1 10021881 - Infections and infestations 10001032 Acute pyelonephritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GR (Completed) LV (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-004893-25 Sponsor Protocol Number: CRO2035 Start Date*: 2014-07-08
    Sponsor Name:Imperial College London
    Full Title: RITUXILUP - An open label randomised multicentre controlled trial of RITUXImab and mycophenolate mofetil (MMF) without oral steroids for the treatment of LUPus nephritis
    Medical condition: Lupus nephritis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-001426-22 Sponsor Protocol Number: ALXN2050-NEPH-201 Start Date*: 2022-05-30
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunogl...
    Medical condition: Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002022-39 Sponsor Protocol Number: WA29748 Start Date*: 2015-09-24
    Sponsor Name:Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd.
    Full Title: A randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety and efficacy of Obinutuzumab in patients with ISN/RPS 2003 class III or IV Lupus Nephritis
    Medical condition: Lupus Nephritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004026-15 Sponsor Protocol Number: AMAG-FER-CKD-354 Start Date*: 2018-05-02
    Sponsor Name:AMAG Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA...
    Medical condition: Iron Deficiency Anemia (IDA) in Pediatric Subjects with Chronic Kidney Disease (CKD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10022974 Iron deficiency anemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) LT (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002507-34 Sponsor Protocol Number: GSN000200 Start Date*: 2014-02-20
    Sponsor Name:Genkyotex Innovation SAS
    Full Title: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study Evaluating the Safety and Efficacy of Oral GKT137831 in Patients with Type 2 Diabetes and Albuminuria
    Medical condition: Patients with type 2 diabetes and albuminuria.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    17.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    17.0 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 22:55:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA